Noro Polymerase and Protease Inhibitors
Program | Discovery | Preclinical | Phase 1 | Phase 2a | Phase 2b | Phase 3 | |
---|---|---|---|---|---|---|---|
Norovirus Gastroenteritis | CDI-988 Oral Protease Inhibitor |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2a Phase not started
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
We continue to identify and develop non-nucleoside polymerase inhibitors using our proprietary structure-based drug design technology platform. In 2020, we entered into a License Agreement with the Kansas State University Research Foundation to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat norovirus and coronavirus infections. Preclinical activities for our Norovirus program are currently under way.